

Pr *Eliquis*[®]
apixaban

#1 DISPENSED NOAC IN CANADA AS PRESCRIBED BY:^{1*}

- Family Medicine/General Practitioners
- Cardiologists
- Neurologists
- Nephrologists
- Geriatricians
- Internal Medicine

ELIQUIS[®] is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective knee or hip replacement surgery; for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF); for the treatment of venous thromboembolic events (deep vein thrombosis [DVT] and pulmonary embolism [PE]) and for the prevention of recurrent DVT and PE.

Please consult the Product Monograph at https://www.bms.com/assets/bms/ca/documents/productmonograph/ELIQUIS_EN_PM.pdf or <https://www.pfizer.ca/pm/en/eliquis.pdf> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-463-6267.

NOAC = non-vitamin K antagonist oral anticoagulant

* Comparative clinical significance unknown.

References: 1. IMS Brogan, Compuscript, November 2018. 2. ELIQUIS Product Monograph. Pfizer Canada ULC and Bristol-Myers Squibb Canada Co.

Pfizer Canada ULC, Kirkland, Quebec H9J 2M5
Bristol-Myers Squibb Canada Co., Montreal, Quebec H4S 0A4

ELIQUIS and the ELIQUIS wave design are registered trademarks of Bristol-Myers Squibb Company used under license by Bristol-Myers Squibb Canada Co.

MEMBER OF
INNOVATIVE MEDICINES CANADA

PRAD



Bristol-Myers Squibb



